Hydroxyprogesterone caproate has been studied in humans at doses as high as 5,000 mg per week by intramuscular injection, with safety and without glucocorticoid effects observed. The medication does interact with the glucocorticoid receptor however; it has about 4% of the affinity of dexamethasone for the rabbit glucocorticoid receptor. But it acts as a partial agonist of the receptor and has no greater efficacy than progesterone in activating the receptor and eliciting associated gene expression in vitro.
Hydroxyprogesterone caproate has been examined in humans at doses as high as 5,000 mg per week via intramuscular injection, with safety and without glucocorticoid effects noted. The medication does interact with the glucocorticoid receptor nonetheless; it has approximately 4% of dexamethasone's affinity for the rabbit glucocorticoid receptor. However, it functions as a partial agonist of the receptor and exhibits no greater efficacy than progesterone in activating the receptor and inducing associated gene expression in vitro.